BrainAurora Medical Technology (SEHK:6681) Loss Deepens To C¥126.4m Testing Growth‑Led Bull Narratives

BrainAurora Medical Technology (SEHK:6681) has laid out its FY 2025 scorecard with first half revenue of C¥100.1 million and a basic EPS loss of C¥0.11, alongside net income excluding extra items of a C¥126.4 million loss. The company has seen revenue move from C¥51.9 million in 1H 2024 to C¥70.4 million in 2H 2024 and then to C¥100.1 million in 1H 2025. Trailing twelve month EPS stands at a loss of C¥0.20 on net income excluding extra items of a C¥210.3 million loss, so investors are left weighing solid top line momentum against margins that remain firmly in loss making territory.

See our full analysis for BrainAurora Medical Technology.

With the headline numbers on the table, the next step is to see how this mix of revenue growth and ongoing losses lines up with the prevailing narratives investors follow around BrainAurora Medical Technology.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM loss of C¥210.3 million keeps profit out of reach

• Over the trailing twelve months, BrainAurora Medical Technology recorded total revenue of C¥170.5 million with a net income loss excluding extra items of C¥210.3 million, so the business is still spending more than it brings in on this time frame.
• What stands out against a more bullish view that focuses on revenue expansion is that losses remain large in absolute terms. C¥126.4 million was lost in 1H 2025 alone, which means any optimism about the business model has to be weighed against the fact that recent revenue levels have not yet brought the company close to breakeven.
  • Bulls often highlight historical loss reduction rates, yet the trailing EPS figure is still a loss of C¥0.20, and each half year in the last three periods has carried a loss above C¥80 million.
  • This keeps the bullish case heavily dependent on future margin improvement rather than any current period evidence of positive net income.

28.4% revenue growth meets rich P/S of 30.2x

• Revenue growth of about 28.4% per year sits alongside a P/S ratio of 30.2x, compared with 5.9x for the Asian Healthcare Services industry and 6.7x for peers, so the market is valuing each C¥1 of sales at several times the sector averages.
• Critics highlight that this premium looks demanding given the business is loss making, and the valuation gap is reinforced by the share price of HK$4.31 trading above a DCF fair value of HK$3.60. Bearish investors see both the 30.2x P/S and the DCF comparison as concrete signs that expectations already embed strong future progress on both growth and profitability.
  • Against that, the historical 28.4% revenue growth rate is the main hard number bulls can point to when arguing that a higher multiple might be justified compared with the 5.9x and 6.7x benchmarks.
  • However, with the company still posting a trailing twelve month loss of C¥210.3 million, the bearish view that the current multiple leaves little room for disappointment is firmly grounded in the reported figures.

On a valuation heavy name like this, it is worth looking at how optimistic and cautious investors frame the story side by side, and where the numbers back them up or push back on them. Curious how numbers become stories that shape markets? Explore Community Narratives.

DCF value HK$3.60 vs market price HK$4.31

• The referenced DCF fair value of HK$3.60 sits below the current share price of HK$4.31, while the company also carries a trailing EPS loss of C¥0.20, so both the cash flow model and the income statement point to a business that is not yet priced on current profitability.
• Bears argue that when a stock trades above a DCF fair value and against a backdrop of persistent losses, it can be more sensitive to any disappointment. That view is supported here by the combination of a DCF gap of roughly HK$0.71, ongoing net income losses of C¥210.3 million over the last twelve months, and recent comments about share price volatility and insider selling in the same three month window.
  • The fact that the P/S stands at 30.2x compared with a 5.9x industry average adds another data point for those who see current pricing as stretched relative to fundamentals.
  • At the same time, the reported 28.4% revenue growth rate is what keeps short term bears from entirely dismissing the name, since stronger top line performance can sometimes narrow DCF gaps if it translates into better future cash flow.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on BrainAurora Medical Technology's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this mix of optimism and caution feels familiar, that is a signal to dig into the numbers yourself and decide where you stand, starting with the 2 key rewards and 2 important warning signs.

See What Else Is Out There

BrainAurora Medical Technology is still recording sizeable losses against its C¥170.5 million in trailing revenue and trades on a rich 30.2x P/S multiple.

If you are uneasy about paying up for a loss making business on a high sales multiple, it is worth checking companies in the 247 high quality undervalued stocks that pair more grounded pricing with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com